ISDA

Deposition Date 2018-10-04

Release Date 2019-01-23

Last Version Date 2024-03-13

Entry Detail

PDB ID:

6MO7

Keywords:

transcription/transcription inhibitor

Title:

N-terminal bromodomain of human BRD2 with N-((4-(3-(N-cyclopentylsulfamoyl)-4-methylphenyl)-3-methylisoxazol-5-yl)methyl)acetamide inhibitor

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.85 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.19

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 2
Gene (Uniprot):BRD2
Chain IDs:A, B, C
Chain Length:126
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:P25440 Pfam ID:PF00439

Ligand Molecules

JWA

Primary Citation

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.

Sperandio, D, Aktoudianakis, V, Babaoglu, K, Chen, X, Elbel, K, Chin, G, Corkey, B, Du, J, Jiang, B, Kobayashi, T, Mackman, R, Martinez, R, Yang, H, Zablocki, J, Kusam, S, Jordan, K, Webb, H, Bates, J.G, Lad, L, Mish, M, Niedziela-Majka, A, Metobo, S, Sapre, A, Hung, M, Jin, D, Fung, W, Kan, E, Eisenberg, G, Larson, N, Newby, Z.E.R, Lansdon, E, Tay, C, Neve, R.M, Shevick, S.L, Breckenridge, D.G.Show

Bioorg. Med. Chem. 27 457 469 (2019)

PMID: 30606676 DOI: 10.1016/j.bmc.2018.11.020

Abstact

The bromodomain and extra-terminal (BET) family of proteins, consisting of the bromodomains containing protein 2 (BRD2), BRD3, BRD4, and the testis-specific BRDT, are key epigenetic regulators of gene transcription and has emerged as an attractive target for anticancer therapy. Herein, we describe the discovery of a novel potent BET bromodomain inhibitor, using a systematic structure-based approach focused on improving potency, metabolic stability, and permeability. The optimized dimethylisoxazole aryl-benzimidazole inhibitor exhibited high potency towards BRD4 and related BET proteins in biochemical and cell-based assays and inhibited tumor growth in two proof-of-concept preclinical animal models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures